Alk-abello A/s Class B · OMXCOP:ALK_B
Alk-abello A/s Class B — Alk-Abello As B Shs New — Q2 2024 Earnings Presentation
12 slides from Alk-abello A/s Class B's earnings presentation, Aug 23, 2024
Slide 1: Q2 2024 presentation
Q2 2024 presentation Webcast 23 August 2024
Slide 2: Agenda and presenters
2 Webcast 23 August 2024 Agenda and presenters • Q2 highlights • Performance o Market trends o Product sales trends o Financials • Strategy President & CEO EVP, Group CFO VP, Head of IR o Allergy+ framework Peter Halling Claus Steensen Sølje Per Plotnikof o Update on key priorities • 2024 outlook Th
Slide 3: Q2 highlights
3 Webcast 23 August 2024 Q2 highlights Financial guidance upgraded to reflect current performance and outlook • 21% growth in total revenue • 32% growth in global tablet sales; driven by 35% growth in EU • EBIT margin of 19% (+10 p.p.) despite one-off restructuring costs • Implementation of Allergy+
Slide 4: Strong momentum in EU sales
4 Webcast 23 August 2024 Strong momentum in EU sales Double-digit growth in all product lines; sales exceeded original forecast • Robust inflow of new AIT patients in past year • Improved pricing, incl. rebate adjustments • Accelerated market transition in Germany; re-bound in France • Efforts to ac
Slide 5: EU and Int'l markets key contributors to growth
5 Webcast 23 August 2024 EU and Int’l markets key contributors to growth Performance in Int’l markets positively impacted by timing of product shipments to Japan and China Europe North America International markets Share of Q2 revenue Share of Q2 revenue Share of Q2 revenue 17% 18% 65% 226m 900m 241
Slide 6: Jext sales is rebounding from supply limitations
6 Webcast 23 August 2024 Jext® sales is rebounding from supply limitations US sales of diagnostics, mainly PRE-PEN®, fell short of expectations Tablets SCIT/SLIT-drops Other products Share of revenue Share of revenue Share of revenue 12% 52% 36% 716m 490m 168m +32% +16% +1% 547m 423m 165m Q2 2024 Q2
Slide 7: Topline growth drives margin improvements
7 Webcast 23 August 2024 Topline growth drives margin improvements DKK 38 million one-off costs included in EBIT result in H1 2024 DKK million H1 2024 H1 2023 Change Gross profit DKKm % 1,000 68 Revenue 2,725 2,369 +15% 800 66 600 Gross profit 1,756 1,506 64 400 62 Gross margin 64.4% 63.6% 200 0 60
Slide 8: Growth aspirations towards 2028
8 Webcast 23 August 2024 Innovate Growth aspirations towards 2028 We will innovate to create a balanced pipeline Revenue EBIT margin NIBD / growth from 2025 EBITDA Life-changing ≥10% Focus allergy solutions Optimise ~25% ≤2 We will grow by focusing on new patient groups and for millions of We will o
Slide 9: Recent strategy highlights
9 Webcast 23 August 2024 Recent strategy highlights Tablet portfolio New product lines Optimization • Regulatory processes to secure • Development projects in peanut allergy • Q2 reorganization of operations approvals of tablets for children usage and anaphylaxis progress as planned • Investments in
Slide 10: Full-year outlook
10 Webcast 23 August 2024 Full-year outlook Upgraded on 22 August 2024 to reflect current performance and outlook for the remainder of the year Revenue Key assumptions • Robust, double-digit growth in EU; mid to high single- DKKm % 14-16% digit growth in North America and Int’l markets 6,000 4,500 2
Slide 11: Q&A session
ORS 0 Ll lat lead aaaail Scare = TPT A
Slide 12: Upcoming news and events
12 Webcast 23 August 2024 Upcoming news and events 26 August Q2 roadshow, Copenhagen 17 September HCA investor seminar (Copenhagen) 25 September SEB Autumn seminar (Copenhagen) 14 November Nine-month interim report (Q3) 2024 Investor Relations: Per Plotnikof, Vice President, Head of Investor Relatio
Alk-Abello As B Shs New — Q2 2024 Earnings Presentation on 6ix